MIRM - Earnings call transcript Q2 2024 | Mirum Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, everyone, and welcome to the Mirum Pharmaceuticals reports second quarter 2024 financial results and provides business update. My name is Carla, and I will be coordinating your call today. [Operator Instructions] I will now hand you over to Andrew McKibben, Vice President of Investor Relations and Finance, to begin. Andrew, please go ahead.

Andrew McKibben

Thanks, Carla, and good afternoon, everyone. you Pharmaceuticals welcome Conference Quarter to Call. like to Second Mirum XXXX I'd by Peetz; company's Officer, CEO, Chief joined news XXXX. Financial our I'm today issued Mirum Chris the Eric our Peter a second our Officer. Earlier of today, and announcing Operating Radovich; our for Chief Quan; Medical the Joanne release Bjerkholt, Chief results Officer, and President quarter release in website. this news and the section of can found SEC Copies be our Investors of filings

its you remind certain that the materially we judgment may on start, to Before discussed. uncertainties we for regarding making statements like this that medicines of today be from These management's actual risks candidates. statements represent as to results call, market forward-looking the and opportunities during cause conference programs including our I'd course based and results differ and Mirum's current and will approved product expectations, of inherently statements involve

duty risk the more Please said, no to filings statements. for like to information. With these our under Chris? Chris. and over SEC XX-Q turn to in are Form I'd factors We subsequent update the call that to refer latest

Christopher Peetz

with progress everyone. made Andrew, the volixibat results. with board good regulatory you and to in important pipeline. achievements outstanding been medicines commercial Thanks, positive share interim quarter and this with excited I'm across the and to afternoon quarter It's our strong we've a continued growth,

the net exclusivity. NDA to with the our if strength, CTX, and population on the steps sales for reach our CHOLBAM, take approved, On grow provide from this last for important XXX% continues $XX.X our will regulatory total a also increase commercial in medicines. orphan us of second opportunity milestones which, an We year. and product of million to commercial underdiagnosed additional side, allow LIVMARLI, representing adoption of we've to chenodiol achieved for quarter across Building CHENODAL medicines submitted

announced see and VANTAGE PFIC, PFIC cholestasis to excited settings interest these be the PFIC to and looking age now Europe. but we another bringing I'm initiation pruritus cholestatic PFIC pruritus for speak this LIVMARLI for to in for to announce seen details, impressive the treatment in to potentially patients the and label limited Alagille to For of We're approved say reduce clinical pruritus. Supported otherwise additional settings, PSC PBC. step and cholestatic the in indication. And from study LIVMARLI high update given to pivotal very pruritus.I'll we also let impact are to cholestatic we label-enabling study the older. that LIVMARLI we've significant the disease estimate alone of forward that are population. I'm would patient some U.S. VISTAS would launching bring least PBC important to and be the advancing potentially we communities an this EXPAND of in positive and We at that studies, PSC U.S. for the data readouts to we multiple response to individually. rare across where took there the and compelling develop Collectively, happy that in study recently the short, towards physicians finally, case is not in interim challenging are syndrome, with XXX months by of Joanne U.S. patients eligible volixibat studies. LIVMARLI, XX towards And patients experience that

medicine quarter and the that to programs. It efficacy to community. VANTAGE readout. pruritus continuing positioned progressing say PSC, Our in in and for enrollment full threshold statistically study The PBC. the a interim to therapies of pack enrollment patient no bring a for the Mirum. With first also were first is both spans is we that well to prespecified PBC results second patient significant this happy exceeded VISTAS in with second-line the in population PSC very I'm study encouraging, are was improvement a study approved

details, I'll over to dive call our into So turn to to the commercial the Peter? business. Peter start with

Peter Radovich

Thanks, by to increase were sales we our U.S., across full-year In X quarter while persist quarter, $XX.X million. Starting compared continue newly sales to million. sales another the commercial all and well be the Chris. million syndrome of same Growth additions to products, $XX.X towards with a XX% and international total forward. prevalent to patients track comprised patient going I'm global diagnosed, strong $XX.X to dynamic revenue of million we represents quarter to driven million, report $XXX expect LIVMARLI, last grew which net pleased product to new were $XXX Alagille continues guidance both year. a this

PFIC are Internationally, beginning diagnosed patients price some was for opportunity to prescriptions patients, saw young. to we include also international that LIVMARLI incremental our Germany. Stemming growth expansion outcome impact label PFIC older negotiations demand our to see that XX provides this, strong, we pleased price generally QX. and when are favorable from months and recent in say achieved given sales and on in children is with a I'm We reference

expect for this which or LIVMARLI benefit next with PFIC and months endorsement also run of happy a recent quarter the X LIVMARLI European these to We We highlights for were patients. very older, of the its X. Commission's course in significant

of year the quarter, demand where the the of continued second Mirum nice the and product recognized CHOLBAM of commercial I'm team's first from half million. Overall, strong growth the continued in we execution. sales CHENODAL performance net thrilled Lastly, in proud $XX.X saw we and with

We million Joanne. to growth. And on guidance I'll over path that, million solid are it turn to $XXX continued Joanne? achieve full-year our with a of $XXX and to

Joanne M. Quan

threshold the this total the a met a and and completing in of The We in Thanks, enrollment changes. with final I'll confirms a PSC in data for patient PBC. BID continuation both analysis VISTAS include exceptional on interim the PSC. efficacy study interim enrolling VANTAGE any recap blinded study by prespecified the the our set for in results. Starting based the without XXXX. had analyses the safety. study and of We're impressive proceeding threshold study second a half We quarter, highlighted for give quick to review an and with with independent Peter. committee VISTAS number the allows the in also the The anticipate study and recommended treatment XX how and effect continue happy these that meaningful is blinded dose milligram analysis. patients us analysis

results Both interim significant advance Moving from for over continue showed with and PBC. on of to volixibat as potential with cholestatic results. substantial volixibat's important X.X-point in thrilled patients consistent in improvement BID the on milligram with statistically itch reduction placebo. and XX We're VANTAGE this, approximately Based the an study pruritus. the a will VANTAGE suffering the dose, the also study. study The VISTAS support doses

Phase play like LIVMARLI study leading can has of results already placebo-controlled improvements believe months. as of results we PBC the conditions to elevated enrollment requests a acids, bile cholestatic persistent like we've acids bile conditions randomized, new atresia, study. in efforts a use variety optimistic of PBC-XX, notably for ramped standard these of burden that of across also has that the in XXX would are on reductions biliary and LIVMARLI received fatigue. a a cholestasis, We talk for share seen up EXPAND such serum treatment over cholestasis. total a this less treatment across enroll up role sclerosing volixibat most path indications. these the addressing multiple larger We patients. ultra-rare are for look the targeting common are We pruritus to significant cholangitis potential of to to pruritus LIVMARLI double-blind, a and EXPAND about secondary We've pruritus evaluating step. Overall, will gears number pruritus. Based with observed Mirum receiving serum for patients bit, cholestatic III the good compassionate is in patients with range in XXXX in EXPAND in dimensions other common use, sites. Shifting I for patients, in some a these study on individuals new responses complete conditions. associated genetic and the with which enrollment compassionate of set suggesting a to pruritus XX significant

Our updates Eric to in look we the it target and in turn EXPAND XX approximately XXXX. I expect to Eric? our financial is further now to VANTAGE forward and discuss to over VISTAS, to patients, quarters. I'll enroll providing on coming complete enrollment results.

Eric Bjerkholt

of press compared quarter million in included results Thanks, that for which we financial revenue a million issued product of million the product million charges, operating operating $XX.X release expense includes of of last $XXX were XX was was $XX.X quarter sales. the the quarter million. second cost expense June SG&A $XX.X ended revenues quarter, Joanne. in I'll second quarter second total million, in Earlier $XX.X to net and R&D the cost million, for expense today, which of expense $XX.X approximately the included for briefly summarize. Net of included sales year. Total $XX.X XXXX million of of The $X.X which noncash

For per the was ended June or 'XX, quarter $X.XX loss share. $XX.X million net XX,

LIVMARLI development milestone of commercial and an of discipline, excellent our financial approval cash, of the the FDA million continued reduction as to quarter. pipeline a a of of end $X.X was June the robust support 'XX, indication. With are equivalents the our Our upon performance we prior million the cash the in PFIC and to investments included position $XXX.X XX, used payment $XX and of our million in Takeda growth commercial of from second Cash quarter business.

Now the over Chris I'll for turn call to final comments. back

Christopher Peetz

year. the execution. Thanks, and Eric. first half It's of our proud been Mirum of I'm team a great strong the

of call medicines, advance adult to advance our priorities: continue to the We to positioned indications and that, are for to pipeline. With volixibat grow the the well open to opportunities approved for look our strategic our questions. continue in please operator, grow commercial expand cholestasis business, X

Operator

our comes Stifel. from And Instructions] Dae from [Operator question Gon first Ha

Dae Gon Ha

progress. clinical. from starting one commercial Congrats I Two with on guess, us, and one commercial. the

Bylvay. and U.S., look the we Alagille between PFIC LIVMARLI label kind across the in at palindrome and As a of approval it's

terms label what VISTAS enrollment there side, So reach pipe? And broaden initiative further trials? any great. the if maybe for comment before on Joanne, experience you expansion I a to sounds Is hoping could implement progressing can then can little perhaps you've enrollment PFIC analog bit from learned the perhaps into come you VANTAGE segment LIVMARLI's accelerate Bylvay's within that in you clinical was down favorably to of and

Christopher Peetz

LIVMARLI, well. follow-up -- has and we've for for just first, out circle for expansion really labeling can how It's But back is the kind think you're gone any asking played On label the what the questions. seen a LIVMARLI. I on comment and sequencing of

as prescribers, I for think indications. Europe, products strong only -- we're we're both very approved a the equal for quite we kind seeing footing, and that's reception been both see think where for both it in indications. world. In where of strong. a now real we're Initial position compelling the very has we for in the data indications, leadership U.S., now in And story we're the we're in tells out what approved play really LIVMARLI

of I comment that the kind let LIVMARLI. strategies. to sequencing, played So Joanne largely enrollment the and in it's think out And label terms maybe favor I'll of of on

Joanne M. Quan

with Like how I enrollment said, the going. is we're happy

interim excited in and been potential And talked that a this share we patient about. we expansion we've seeing impact sites We're previously very the noticed, by and you've As medicine they our for the PBC the populations. and are really our with investigators. work both PSC continuing continuing the analysis as and excitement share has the existing results to that with as the that on

enrollment with going. happy is we're where So our

Operator

Partners. The Leerink next Mani question from from comes Foroohar

Mani Foroohar

ones. quick of couple A

population us it's about the population? see First, when heterogeneous you that then follow-up. of a think recognizing cholestatic give a time you and study quick of bit think how And pruritus, the commercial of we might results, expansion novel which sense we duration the can a little about have a horizon in you

Christopher Peetz

follow-up. Maybe Joanne, Peter the take let and I'll

Joanne M. Quan

Sure.

bit atresia So on now, this a that some based the we our It use. but variety enrollment we of expect And we sclerosing in patients cholangitis is have other cause, secondary experience a will a as and to as are of patients, we XXXX. causes. biliary compassionate really a heterogeneous some then and plan of group in complete launching just study said, is

wide of IBAT of in a role that these think to So study. of patients this difficult -- in of treatment variety would we're of actually and our pretty to the who understanding of its confident extends be terms potential cholestatic each inhibitors pruritus use

study them this in we results EXPAND use. wider and some and hope So we're some to support get study excited all

Mani Foroohar

commercial -- That's think side, helpful. market. element a you on there's there's little bit of then the seasonality a sort some of And in about when more this of obviously,

of And should adds? XQ so way the ago. any swing years seasonality terms new looking think sort about the certainly a in think pendulum forward? in operational tends about tempo of year next around And other as swings saw details few patient the one we of of the couple early we quarters we How to across the and should

Peter Radovich

thing effect that on as our say as the strong on And across X products, in Change mean quite lead volume, relatively did the of just identified another, mean rare you we've can't to keep products to we here. quarter thing U.S. to a say I That's the bile see they're any really reflecting to whether and there's quarter-to-quarter these one products can't kind impact ultra-rare with in think I in LIVMARLI occurs kind quarter-to-quarter low with seasonality remind there. But back I kind trends that mind that I QX cyberattacks. of of Healthcare which as the real number one in versus underlying products. far frankly. from one about goes acid can variability, QX, seasonality to

Mani Foroohar

we we And out? sort the eroding of sort Is of sort that horizon we Okay. that over should the -- how quarters? recurring think next course itself, think to something of model? sort what of should primarily Is -- Like we event? dynamics into XQ, on we and of that couple should should of time of play referenced and XQ about pricing out about expect OUS baking sort playing how

Peter Radovich

the saw QX. We exactly. in Yes, effect

of effect demand QX, We gone that of by expect we're to line. all is top kind through And the our that, in growth expectation the QX. that flows time volume the you're and it seeing into is

Operator

Gavin from from comes question next ISI. Clark-Gartner Our Evercore

Unknown Analyst

And This for Gavin. ] is [ X. have Yesha we just

XX then after for EXPAND sample maybe first just that The on follow-up patients one, touch And you one little study? in could and size you powered the how confidence that. the

Christopher Peetz

of kind these some kind if acids I I'll a bit. dose to this the Joanne you the IBAT drive one in here of that pruritus. let think at at response really to I bile dramatic settings, point, seen say think think we've a is now, I and But thing give on context right comment that here pattern cholestatic can you're

the design profile is actually of patients. on So use seen play that same number having out the thinking compassionate behind based study a in

So strong we've really aggregate, the basically that, individual case make in from studies evidence this population.

size. and to the speak study. feel why together. That's designed bit that's us sample Maybe what it little good we compelled launching we can it a So about put Joanne about

Joanne M. Quan

So size based sample powering primary was is an based on our the which on endpoint, observer-rated feature.

prior we So this experience well understand with on studies is based in a previous scale that LIVRAMLI. our

pretty So us effect. solid sample we this that is an feel appropriate treatment confident see to a size for

Unknown Analyst

enrolling one And you data any trial? Awesome. BA makes this follow-up. patients EMBARK then from Was there confident that in

Christopher Peetz

that to back I'll Joanne. pass

Joanne M. Quan

Yes.

atresia, in were is I we're think enroll With EMBARK. the than biliary have that taking the of a important severe number did patients of had they course it's of we're years over Kasai that deteriorates a patient their really to EXPAND different And ago, their these population in ones of EXPAND, and journey. enrolling actually the that develop note condition pruritus. may for but at any many that quite will time, point really we patients --

this is around time So really Kasai. they where than different a EMBARK, we incident population had quite that patients a took the

cholestatic pruritus that, patient population. with of including causes liver other disease. So a different chronic this And of on we're is top quite a

Christopher Peetz

that. IBAT kind as you In age, been quite treatment. they're compassionate hallmark response patients than [ those do the Yesha older bit I'd studies, where there, also there see ], add infants. of to on atresia in biliary And have a enrolled a case use EMBARK

what we've advance settings in. So to figured dose these now how to medicines them I and out think

Operator

question Jessica Fye comes JPMorgan. from next from The

Jessica Fye

few. a had I

then levels And look defined or First, results? where are Could by broken data should the you? And we where of of disease more type on see disease assets those on PBC-XX? And down just dimension in should as PBC detail of we ALP the you severity for presentation a when about on more? details itch development we to interim separately, expect business front, of observed what kind for volixibat? the expect learn what liver should For which can present can bit biomarkers we estate improvements data subgroups LIVMARLI color of and volixibat there currently the across are additional results of have additional most just your IP and provide the example, of or fatigue by and you lastly, terms to IP comment interesting any you pending areas on you what in applications?

Christopher Peetz

I can over BD PBC comment it then and at on talk we and upcoming our congress. an preparing to further Peter strategy. I'll and last, maybe what's first abstract. submitted the that it And kind of a I'll the about shot pass it. in the where lands -- really for can't to predict We're getting the first from on and study. We'll data work when an take

and of So and unique a intellectual the more there abstract. And particular I'll there's in here. slides in -- materials that summary tie advances have Maybe to the just IBAT I'll about talk we're family talked that number general that we're LIVMARLI of -- a for these can in that's and patents actually dosing recently say great across profile BD you back the to And on and about volixibat that backup to seen can really public for we've our detail quite talking Peter of programs strategy. been in our consider the elements the all this reference. on to you XXXX there corporate backup property, about you direct granted then that added pending we at of the that deck of that highlight that's looking led

Peter Radovich

the a underappreciated opportunities. of we programs rare Sure. like value, programs. really disease. could where rare lot We're question Essentially -- in ourselves pediatric We asking focused add

commercial in disease. strong regulatory, group really a development, rare have We

So corridor. have of looking we disciplined. in a kind We're high that And bar. a very

base a it. with in have We of strong a catalysts really of runway front business great

a to of these scrutiny So take lot opportunities. we

Operator

next The from Stanley. question Morgan comes Mike from Ulz

Unknown Analyst

Robin on for is This Mike.

in talk are below the about how then Just label patients do PFIC, And what many are to XX you XX months? there is? opportunity typically and pursue to just expansion a below months can you that patients expect diagnosed

Christopher Peetz

now feel really that in expansion PFIC our label we months, to down a it's Overall, this strong place. XX with

that's on We that submit on decision with I we sNDA based do to to a the come yet We're data yet. what similar haven't evaluating are another mature. -- to Alagille. But infant the potential frankly, now

that we're something pursue. position capture it's patients We syndrome both So most could where we for we a feel and LIVMARLI-targeted like in of now Alagille the PFIC.

Operator

next The Citi. from Lebowitz question comes David from

David Lebowitz

to the EXPAND you given a respect expansion do population, view think how perspective? trial would the FDA it the from heterogeneous With label

Christopher Peetz

I'll little discussion that a with thinking into ask some that went the the of to talk FDA. maybe Joanne and about bit

Joanne M. Quan

about Interesting designed don't suggested because So the EXPAND in study the Yes. FDA in question it. so put you that you at point "Why one -- way the into study this -- came receiving We these the keeping has that mind. a compassionate use request, been actually FDA because were asked fact, and study?" said, had the that input

so the that pruritus has elevated and [indiscernible]. that think on acids, serum we we pruritus, effect know do has it cholestatic And cholestasis, in -- really is commonality the bile this

in once, executed. our I the see ability confident we terms results in pretty that of think, of the it's to execute study and we're really terms So

Operator

James is Raymond question from Steven The from next Inc. Financial Seedhouse

Steven Seedhouse

measuring seems pruritus, curious Just you're you patients like this to the would include on the disease how endpoint So it trial conditions? and because going going adult on types? just be pediatric measuring across EXPAND, I'm standardize to depending how are

Joanne M. Quan

has experience and ItchRO, really observer-rated have pediatric studies. do prior population. been we that's with an in designed for have validated We which And which

with different endpoint to of design confident how the study know of But the recognize fact So have in that we and and adult population of of versus a to it's we pretty the this terms endpoint in feel it. use pediatric we that you right endpoints. can have the the experience selection and

Christopher Peetz

on of follow-up That that's kind the And that's the where Yes. is. XX kind primary and that. just data analysis cohort, of primary patients, pediatric to set,

of the pediatric is adult a in cohort. way. of supplemental Some that score. the of plan analysis part And think will scores be on designed based Primary

Steven Seedhouse

And second self-reported would Or so be does the look How a endpoint adults observer? itch? the for there both? would be

Joanne M. Quan

Right.

believe we're discussions be But majority adults, will reason a use, pediatric. So a will separate just on with in adult it's with for we of And X. do analyze experience a those compassionate studying and to in the one clinicians think patients for there cohort. endpoint. we them our that's them us some supplemental self-reported from the be so the do having and patients, Based our

Steven Seedhouse

is Okay. commercially here, that's same And then available? formulation the this just the formulation to going be liquid

Christopher Peetz

That's right. Yes.

Steven Seedhouse

maybe to enrolled either question. to who's that enroll last just Okay. study? for in And Are pruritic anyone excluding patients multipart for -- this Or enrollment, and eligible treated question EXPAND? -- to thanks that excuse the EMBARK in in that prior atresia and LIVMARLI? anyone that's been me, then in on with enroll eligible you is compassionately are enrolled biliary EXPAND were exposure Or

Christopher Peetz

first, the -- in The population on the too really they pruritus young, most Well, the on to for part. were was just EMBARK recognize even young differences reiterate to so setting. the

looking time that see would show the been very after the don't even up at. that EMBARK was basically until period have -- what You

go So grade getting age it's be? instances. going Think to of lot towards of what setting a -- these them after to very for a distinct children are school as they

Steven Seedhouse

some on patient? EMBARK, in bile follow-up or Chris. there metric a eligible or they just responded biliary So acids to If they're EXPAND enroll by bilirubin if atresia that that, are in are patients

Christopher Peetz

them expect The you're response Kasai they progress there in EMBARK had several or a seeing not for that recall results, that really wouldn't signal, patients years, already. study we transplant procedures, a those successful to had again setting, Yes. you right? either So --

was of a just it question. now, such different a know patient of even population. -- circle don't I didn't We relevant kind back as it's really the on head we top it's my off can it So -- the but exclusion -- -- see right it's criteria

necessarily those see connect. wouldn't You

Operator

Brian next from comes question Baird. from The Skorney

Unknown Analyst

on for Charlie Brian. is This

was around Just bile of it portfolio. acid mid-XX per on quarter. questions a couple to Previously, low- the sitting

more said could CHOLBAM? So there? value out opportunities to you're you're seeing, just well for but you're getting a give if what it's -- growth, the demand any planning detail expand little wondering you as if As you of other

Christopher Peetz

I'll ask some Peter give to color.

Peter Radovich

And that acid I you're claim what bile -- artificially looking pharmacy that products the to that a back processing Yes. the if at think that versus go of cyberattack was kind the QX, in QX because just QX low U.S. of occurred impacted I'd reminder

with is expect is one established. dynamic with demand across that So that historical yes, there label a kind just product to these the keep various of of seen line that over with in in where CHOLBAM mind. and It kind you you've -- do averages spot. use steady what been is facilitates variability We time reimbursement the growth we think in of terms the of great CHOLBAM settings quarter-to-quarter and expansion, in it's products. And reminding

to major there. no expansion on focus plans right now So

Operator

Jon from from JMP. comes question Citizens next The Wolleben

Jonathan Wolleben

with year? wanted improve me. on that PFIC the of without expansion PFIC A the going Wondering propylene clinical the in Things observation is couple here, you throughout well. you in the FDA Things of this the toxicity? talking include? that metrics Any to are the risk could -- guys launch sales of discuss for the any glycol risk rest on the upon recently, about a that Or just trials? And then label added can U.S.

Christopher Peetz

Peter talk commercial the Joanne between up to aspects. and of safety about break kind that and I'll

Peter Radovich

Have -- we've how from of That we had access PFIC. with a patients well. commercial with transition very happy number seen clinical the out gate our proceeded come drug. real trials, expanded to of programs Certainly,

well pretty modest in expect patients that As be before reimbursement. in. given PFIC as it contribution talked to We've from to PFIC revenue novo about de we prescriptions come XXXX for

We XXXX for be expect is really drug more. contemplated a bit PFIC guidance, starts free but a shipment in contributing where this to our year fair bit expect little of PFIC. It

with regards that. program, to the start. And So clinical let propylene to a Joanne glycol speak good I'll development the and then

Joanne M. Quan

This our kind PG clinical in of And all being not labels, of label we context FDA be Just instance. toxicity that with light expansion. the studies. -- seen have carefully considered in patients pretty for seen really PFIC data. the FDA for considered experience to and have in patient arose PG warned expansion, the the from the younger clear, concern and other And of of about we the looked toxicity we

So that for, the feel patients, what this not We look new they comfortable are know physicians they're this prescribing their us. monitoring. is to appropriately to who know do

So from is handled that of terms we patient this think a routine practical the perspective in care. well

Operator

And Arce question the is Ed next from H.C. Wainwright. from

Wing Yip

This substituting how for Perhaps as first, opportunity couple in relative to ]. also an Ed. of CHENODAL got indication, questions suppose of quantity a for is you [ on-label Thomas wondering in Yip I CTX CHENODAL terms and just the do existing characterize additional commercial I sales.

Christopher Peetz

for I'll that, ask Peter CTX. population to undiagnosed comment on give the some on color

Peter Radovich

market literature, patients of probably the the As X,XXX CTX between the now. United But States. research, KOLs, best right X,XXX opportunity, are somewhere from and those we diagnosed with CTX prevalent look XX% estimates in at only

what we best see. the of it's So estimate

increase higher. biggest that the opportunity XX% probably So is we can to if something

journey may product kind see before. to the various these interest from awareness is symptoms on never other take and as patients both been with increase are of in have that. promoted rate we interest in physicians time initiatives, chenodiol to able as approved FDA has well a get disease their who and presenting they're as the to to trying out So speed of reaching diagnosis investing up state if And the to and then seen promote a to -- we're lot by diagnosis. certainly, physicians the neurologists prescribers, of And diagnosis

benefits benefits get even for the the there diagnosis awareness like of be out of opportunity So reimbursement, and, an things clinic, I patients raise support chenodiol, think of that. to there'll -- in potential

Wing Yip

Understood. from us. And maybe more one

Just one volixibat. for

agencies? far? has interim so reviewed regulatory any Regarding EMA the feedback data the VANTAGE have FDA and VISTAS, Any that you or the from

Peter Radovich

cadence discussion of here plans we a designing we be have our is pre-IND are. would regulatory In And have what results, had studies. the review, final the next after opportunity the

interim of plans. discussions kind no So on

Operator

our was that last And question.

for any CEO, back final hand Peetz, will the I over remarks. So to Chris

Christopher Peetz

Thank you, for and joining today. for operator, our appreciate We Have good you the Mirum evening. thank support programs. Bye. and all a us

Operator

Thank And this today's call. concludes you joining. for

You disconnect the may from now call.

Mirum Pharmaceuticals (MIRM) 7 Aug 242024 Q2 Earnings call transcript